Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tramadol hydrochloride, quantity: 300 mg - tablet, modified release - excipient ingredients: povidone; polyvinyl acetate; colloidal anhydrous silica; hydrogenated vegetable oil; xanthan gum; hydroxypropyl distarch phosphate; magnesium stearate; sodium lauryl sulfate - indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. not indicated for use in chronic non-cancer pain other than in exceptional circumstances. not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: hydrogenated vegetable oil; povidone; hydroxypropyl distarch phosphate; sodium lauryl sulfate; xanthan gum; magnesium stearate; polyvinyl acetate; colloidal anhydrous silica - indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. not indicated for use in chronic non-cancer pain other than in exceptional circumstances. not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tramadol hydrochloride, quantity: 100 mg - tablet, modified release - excipient ingredients: hydrogenated vegetable oil; sodium lauryl sulfate; colloidal anhydrous silica; hydroxypropyl distarch phosphate; povidone; magnesium stearate; polyvinyl acetate; xanthan gum - indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. not indicated for use in chronic non-cancer pain other than in exceptional circumstances. not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk; sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk: sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - codeine phosphate hemihydrate, quantity: 5 mg/ml - oral liquid - excipient ingredients: glycerol; propylene glycol; purified water; sucrose; methyl hydroxybenzoate - relief of unproductive, dry and intractable coughs associated with colds and flu relief of unproductive, dry and intractable coughs associated with colds and flu.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 40 mg - capsule, hard - excipient ingredients: titanium dioxide; lactose monohydrate; iron oxide black; magnesium stearate; sunset yellow fcf; liquid paraffin; sodium polystyrene sulfonate; erythrosine; gelatin; silicon dioxide; sodium lauryl sulfate - metermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with metermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 30 mg - capsule, hard - excipient ingredients: liquid paraffin; magnesium stearate; iron oxide red; lactose monohydrate; sodium polystyrene sulfonate; titanium dioxide; iron oxide black; gelatin; silicon dioxide; sodium lauryl sulfate - metermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with metermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: iron oxide black; lactose monohydrate; iron oxide yellow; sodium polystyrene sulfonate; liquid paraffin; titanium dioxide; brilliant blue fcf; magnesium stearate; gelatin; silicon dioxide; sodium lauryl sulfate - metermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with metermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phentermine, quantity: 30 mg - capsule, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; sodium polystyrene sulfonate; liquid paraffin; iron oxide red; iron oxide black; titanium dioxide; gelatin; silicon dioxide; sodium lauryl sulfate - duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with duromine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.